Insight

John Simmerling: An incredible microscopy of a ferocious, activated T-cell, killing a cancer cell

John Simmerling/LinkedIn

Dec 23, 2024, 15:38

John Simmerling: An incredible microscopy of a ferocious, activated T-cell, killing a cancer cell

John Simmerling, Chief Science Officer at Biomedical and Healthcare Technology Solutions Group, shared a post on LinkedIn:

“Credit Nanolive SA. This is an incredible microscopy of a ferocious, activated T-cell, killing a cancer cell. Yet, before the killer T-cell can identify and execute a foreign cell (in this case, cancer), it needs a helping hand.

It needs the scout team, the hall monitors, the spies, the informers, the dendritic cells.

When the Dendritic scouts spot an unrecognizable cell, like cancer, virus, bacteria, or foreign particles, they “ingest” it and chop it into smaller pieces.

This process enables the antigen to be presented to the T helper cells, which help activate the immune system to its greatest potential by coordinating other immune cells through battle.

T cells ‘mature’ in the Thymus. T-cells that recognize MHC Class I molecules become CD8- T cells. T-cells that recognize MHC Class II molecules become CD4 T-cells. CD-8 T cells can process the execution of the recognized foreign material, or CD-4 cells can.

We note that CD-4 cells are also an important part of activating the body’s immune response, including the recruitment of activated CD-8 cells.

This process is the foundation of CAR-T therapy, where precision targeting involves developing cancer drugs to help target specific cancer cells. For example, bispecific antibodies are being developed to attach to cancer cells, deliver target drugs, and help recruit Killer CD-8 T-cells.

See the full video.”

James Crowley, Professor of Medicine Emeritus at Brown University, shared this post, adding:

“T cells ‘mature’ in the Thymus. T-cells that recognize MHC Class I molecules become CD8- T cells. T-cells that recognize MHC Class II molecules become CD4 T-cells.

This process is the foundation of CAR-T therapy, where precision targeting involves developing cancer drugs to help target specific cancer cells. For example, bispecific antibodies are being created to attach to cancer cells that can attract cancer-killing T cells to the cancers.”

More posts featuring James Crowley.

John Simmerling is the Chief Science Officer at the Biomedical and Healthcare Technology Solutions Group. Previously, he served as Chief Science Officer for the Infectious Disease Biotechnology Organization.

His career includes leadership roles such as Senior Business Development Manager for Precision Medicine in Oncology at Philips and Regional Vice President and Subject Matter Expert in Medical and Radiation Oncology Pathways at NantHealth.

James P. Crowley is a Professor of Medicine Emeritus at Brown University and serves as a volunteer physician at the Rhode Island Free Clinic. He has held leadership positions in the medical community, including past President of the Rhode Island Medical Society and the last President of The Providence Medical Association.